1. Ivosidenib in IDH1‐mutant, chemotherapy‐refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double‐blind, placebo‐controlled, phase 3 study;Abou‐Alfa G.K.;Lancet,2020
2. Dichotomy in intrahepatic cholangiocarcinomas based on histologic similarities to hilar cholangiocarcinomas
3. Genomic analyses identify molecular subtypes of pancreatic cancer
4. Adenosquamous carcinoma of the pancreas: molecular characterization of 23 patients along with a literature review;Borazanci E.;World J Gastrointes Oncol,2015
5. Molecular perturbations in cholangiocarcinoma: Is it time for precision medicine?